The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation

Inclusion Criteria: * Age ≥ 18 and ≤ 80 years at the time of signing the informed consent * Subjects with brain arteriovenous malformation diagnosed by CT/MRI/DSA * The target brain arteriovenous malformation is classified by Spetzler-Martin in the range of Ⅰ \~ Ⅳ * Subjects themselves and/or their guardian are able to understand the purpose of the study, consent to participate, and sign the informed consent form * Brain arteriovenous malformations deemed suitable for liquid embolic agent intervention as assessed by the investigator Exclusion Criteria: * Multiple brain arteriovenous malformations * Brain arteriovenous malformation complicated with blood flow-related aneurysm that may require staged and delayed treatment using other methods within the one-year follow-up period * Brain arteriovenous malformation with a history of stereotactic radiosurgery within 3 years * Brain arteriovenous malformation with bleeding within 1 week * Brain arteriovenous malformation with an expected number of embolizations ≥ 4 * Brain arteriovenous malformation scheduled for surgical resection after embolization * mRS score ≥ 3 * Subjects unsuitable for anesthesia or endovascular surgical treatment, due to major diseases of cardio, lung, liver, spleen or kidney, malignant brain tumors, severe active infection, disseminated intravascular coagulation, or a history of severe mental illness, etc * Subjects who undergo major surgical procedures (such as tumor resection, vital organ surgery, etc.)…